Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 13/20 | 0.73 |
| ▸ | MME | P08473 | 11/20 | 0.73 |
| ▸ | CPA1 | P15085 | 6/20 | 0.73 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.73 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31202567 | 1.00 | ACE (0.73) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL30411231 | 1.00 | ACE (0.73) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL29669675 | 1.00 | ACE (0.73) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL7685718 | 1.00 | ACE (0.73) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL4261774 | 1.00 | ACE (0.73) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL7128864 | 1.00 | ACE (0.73) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL29822555 | 0.97 | ACE (0.70) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL31089980 | 0.95 | ACE (0.67) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL30895730 | 0.94 | ACE (0.65) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL7678279 | 0.94 | ACE (0.65) | ACEMMECPA1ACE2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) | 2026-03-12 | — | — | US | claimed |
| US-20240426830-A1 | CHRONIC WOUND HEALING BIOMARKER DIAGNOSTICS | THE TRUSTEES OF INDIANA UNIVERSITY | 2024-12-26 | — | — | US | claimed |
| CN-118987163-A | Use of sardine peptide-containing composition for improving atopic dermatitis symptoms | 海口桥水联合科技有限责任公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024235082-A1 | USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS | 海口桥水联合科技有限责任公司 | 2024-11-21 | — | — | WO | claimed |
| CN-115073550-B | Dipeptide difunctional small molecule compound for activating enzyme catalytic reaction and application thereof | 中国科学院青岛生物能源与过程研究所 | 2024-10-08 | — | — | CN | claimed |
| CN-116350746-B | Application of sardine peptide composition in medicines for treating allergic rhinitis | 海口桥水联合科技有限责任公司 | 2024-03-22 | — | — | CN | claimed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-116350746-A | Application of sardine peptide composition in medicines for treating allergic rhinitis | 海口桥水联合科技有限责任公司 | 2023-06-30 | — | — | CN | claimed |
| WO-2023069598-A1 | CHRONIC WOUND HEALING BIOMARKER DIAGNOSTICS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2023-04-27 | — | — | WO | claimed |
| US-9650415-B2 | Uric acid-lowering agent | SUNTORY HOLDINGS LIMITED (JP) | 2017-05-16 | — | — | US | claimed |
| CN-105407907-A | Uric acid level lowering agent | SUNTORY HOLDINGS LTD | 2016-03-16 | — | — | CN | claimed |
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-12630631-B2 | Inhibition of platelet aggregation using anti- human gpvi antibodies | ACTICOR BIOTECH (FR) | 2026-05-19 | — | — | US | disclosed |
| US-20260132222-A1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026089754-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| JP-2002284647-A | HAIR RESTORER | COSMO PRODUCTS KK | 2002-10-03 | — | — | JP | disclosed |
| JP-2002284668-A | PREVENTIVE AND THERAPEUTIC AGENT AGAINST DARKENING | COSMO PRODUCTS KK | 2002-10-03 | — | — | JP | disclosed |
| US-5036052-A | Containing a dipeptide of tryptophan and alanine or lecine and no stabilizer; discoloration inhibition | MORISHITA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-30 | — | — | US | disclosed |
| EP-0347890-A1 | Amino acid nutrient compositions | Roussel Morishita Co., Ltd. (JP) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132222-A1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | SSB, IGSF11, CD22 | ACE 4384/4885MME 3398/4885CPA1 759/4885 |
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | OPRK1, TPH1, HTR3C | ACE 4214/4885MME 2885/4885CPA1 1242/4885 |
| US-12630631-B2 | Inhibition of platelet aggregation using anti- human gpvi antibodies | IGLV6-57, GP6, VSIG8 | ACE 4465/4885MME 4088/4885CPA1 2572/4885 |
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | VIP, ANPEP, RNPEP | ACE 132/4885MME 112/4885CPA1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.